A5086791040- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Ovarian cancer diagnosis and treatment
- Breast Lesions and Carcinomas
- Endometrial and Cervical Cancer Treatments
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Bone health and treatments
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Metastasis and carcinoma case studies
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Cancer, Hypoxia, and Metabolism
- Endometriosis Research and Treatment
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Epigenetics and DNA Methylation
Heinrich Heine University Düsseldorf
2016-2025
Düsseldorf University Hospital
2016-2025
Centrum für Integrierte Onkologie
2023-2025
University Hospital Cologne
2013-2025
Klinik für Frauenheilkunde
2013-2024
Life Science Center Düsseldorf (Germany)
2018-2024
Integrated Oncology (United States)
2023
Universitäts Frauenklinik
2011-2022
Diakonissenkrankenhaus
2022
Merck & Co., Inc., Rahway, NJ, USA (United States)
2021
We assessed the prognostic significance of presence micrometastasis in bone marrow at time diagnosis breast cancer by means a pooled analysis.
Abstract Purpose: The purpose of this study was to test the hypothesis that circulating tumor cells (CTCs) are present in patients many years after mastectomy without evidence disease and these CTCs shed from persisting with breast cancer dormancy. Experimental Design: We searched for 36 dormancy candidate 26 age-matched controls using stringent criteria cytomorphology, immunophenotype, aneusomy. Results: Thirteen candidates, 7 22 clinical disease, had CTCs, usually on more than one...
The persistence of circulating tumor cells (CTC) in breast cancer patients might be associated with stem cell like which have been suggested to the active source metastatic spread primary tumors. Furthermore, these also may undergo phenotypic changes, known as epithelial-mesenchymal transition (EMT), allows them travel site metastasis formation without getting affected by conventional treatment. Here we evaluated 226 blood samples 39 during a follow-up palliative chemo-, antibody - or...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over course disease concordant between primary tumor metastases. Therefore, patients with -negative tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used capture circulating cells (CTCs) evaluate their gene status by fluorescence situ hybridization. The corresponding CTCs 31 showed 97% agreement, no false positives. In 10 -positive...
This study was aimed at detecting and characterizing circulating tumor cells (CTC) before after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer.The clinical trial GeparQuattro incorporated NT approaches (epirubicin/cyclophosphamide prior to randomization docetaxel alone, combination capecitabine, or followed by capecitabine) additional trastuzumab treatment for HER2-positive tumors. We used Food Drug Administration-approved CellSearch system CTC detection...
Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in peripheral blood patients with metastatic breast cancer, less is available for CTCs at time primary diagnosis.We conducted a pooled analysis individual data from 3,173 nonmetastatic (stage I-III) cancer five institutions. The prevalence and numbers were assessed diagnosis FDA-cleared CellSearch System (Janssen Diagnostics, LLC). Patient outcomes analyzed using meta-analytic procedures,...
We aimed to determine the prognosis of patients with breast cancer diagnosed during pregnancy (BCP).In this cohort study, a multicentric registry BCP (from Cancer in Pregnancy, Leuven, Belgium, and GBG 29/BIG 02-03) compiled pro- retrospectively between 2003 2011 was compared who did not have associated pregnancies, using an age limit 45 years. Patients diagnosis postpartum were excluded. The main analysis performed Cox proportional hazards regression disease-free survival (DFS) overall (OS)...
Purpose Observational studies suggested that luteinizing hormone–releasing hormone agonists (LHRHa) might prevent premature ovarian failure resulting from adjuvant chemotherapy in premenopausal patients. We aimed to test the efficacy of function preservation with LHRHa goserelin patients breast cancer. Patients and Methods In a prospective, randomized, open-label, controlled multicenter study, 60 younger than age 46 years hormone-insensitive cancer were allocated receive...
The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like which have been suggested to the active source metastatic spread primary tumors. Furthermore, able disseminate and metastasize, CTC must perform epithelial-mesenchymal transition (EMT). We studied expression three EMT markers cell marker ALDH1 from 502 patients. Data were correlated disseminated (DTC) bone marrow (BM) clinicopathological data patients.A total 2 × 5 ml blood was analyzed for...
MicroRNAs (miRNAs) as modulators of gene expression have been described to display both tumor-promoting and tumor-suppressive functions. Although their role has studied in different tumor types, little is known about how they regulate nuclear factor κB (NF-κB) signaling breast cancer. Here, we performed an unbiased whole genome miRNA (miRome) screen identify novel NF-κB pathway The identified 13 families whose members induced consistent effects on activity. Among those, the miR-520/373...
The therapeutic effect of tamoxifen depends on active metabolites, e.g., cytochrome P450 2D6 (CYP2D6) mediated formation endoxifen. To test for additional relationships, 236 breast cancer patients were genotyped CYP2D6, CYP2C9, CYP2B6, CYP2C19, CYP3A5, UGT1A4, UGT2B7, and UGT2B15; also, plasma concentrations 22 its including the (E)-, (Z)-, 3-, 4′-hydroxymetabolites as well their glucuronides, quantified using liquid chromatography–tandem mass spectrometry (MS). activity levels metabolites...
Abstract Several hundred clinical trials currently explore the role of circulating tumor cell ( CTC ) analysis for therapy decisions, but assays are lacking comprehensive molecular characterization s with diagnostic precision. We therefore combined a workflow enrichment and isolation pure CTCs non‐random whole genome amplification method single cells applied it to 510 189 leukocytes 66 ‐positive breast cancer patients. defined integrity index GII identify suited by different assays, such as...
The prognostic significance of disseminated tumor cells (DTC) in bone marrow (BM) breast cancer patients at the time primary diagnosis has been confirmed by a large pooled analysis. In view lack early indicators for secondary adjuvant treatment, we here evaluated whether persistence DTCs after therapy increases risk subsequent relapse and death.Individual patient data from 676 women with stages I-III 3 follow-up studies were pooled. During clinical follow-up, underwent BM aspiration (BMA) to...